​Hormone replacement therapy, or HRT, was the first menopause treatment available to women, approved by the FDA in 1941. It ...

Menopause care innovations include at-home hormone testing, virtual appointments, and new non-hormonal therapies for symptom ...

Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring ...

The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...

A growing number of women are turning to testosterone treatments to ease their menopause symptoms — and save their sex lives.

Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire ...

Despite more than a third of women reporting moderate to severe menopause symptoms in 2021, few sought treatment, according ...

Addyi (flibanserin) was cleared a decade ago to treat low sex drive in women before menopause. A new FDA action allows ...

On December 15, 2025, the U.S. Food and Drug Administration approved the medication Addyi for the treatment of hypoactive ...

Impulsive, anxious, overheated, scatter-brained, depressed and in pain are just some of the terms that many women use to describe themselves when they reach perimenopause, or the years that ...

Review of 1 million women finds no clear link between hormone therapy and dementia risk. Evidence certainty is low with ...

The FDA expanded its approval of Addyi to treat low libido in postmenopausal women up to age 65. The approval will open up ...